



## Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast

April 22, 2021

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- [Genocea Biosciences, Inc.](#) (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, April 29 at 8:30 a.m. ET.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 2191366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at <https://ir.genocea.com/events-presentations>.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

### **About Genocea Biosciences, Inc.**

Genocea's mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit <https://www.genocea.com>.

### **Investor Contact:**

Dan Ferry  
617-430-7576  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)